Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ogg1tm1Yun mutation
(1 available);
any
Ogg1 mutation
(23 available)
|
|
|
neoplasm
|
|
• spontaneously developed in Ogg1 knockout mice approximately 1.5 years after birth
|
|
|
• spontaneously developed in Ogg1 knockout mice approximately 1.5 years after birth
|
respiratory system
|
|
• spontaneously developed in Ogg1 knockout mice approximately 1.5 years after birth
|
|
|
• spontaneously developed in Ogg1 knockout mice approximately 1.5 years after birth
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ogg1tm1Yun mutation
(1 available);
any
Ogg1 mutation
(23 available)
|
|
|
nervous system
behavior/neurological
cellular
homeostasis/metabolism
immune system
hematopoietic system
neoplasm
|
|
• mice are highly susceptible to spontaneous tumorigenesis within 100 days of birth
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nudt1tm1Tts mutation
(0 available);
any
Nudt1 mutation
(31 available)
Ogg1tm1Yun mutation
(1 available);
any
Ogg1 mutation
(23 available)
|
|
|
neoplasm
|
N |
• no tumors in the lungs of double knockout mice, unlike Oggtm1Skmi single knockout mice
|
nervous system
|
|
• 3-NP-treated mice exhibit better motor performance with neither medium spiny neuron loss, microgliosis nor single strand break accumulation compared with Ogg1tm1Skmi homozygotes
|
cellular
|
|
• 3-NP-treated mice exhibit better motor performance with neither medium spiny neuron loss, microgliosis nor single strand break accumulation compared with Ogg1tm1Skmi homozygotes
|
homeostasis/metabolism
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nudt1tm1Tts mutation
(0 available);
any
Nudt1 mutation
(31 available)
Ogg1tm1Yun mutation
(1 available);
any
Ogg1 mutation
(23 available)
|
|
|
nervous system
|
|
• striatal degeneration in 3-NP-treated mice
• however, calpain and PARP inhibitors suppress striatal neurodegeneration and behavioral impairments
|
|
|
• in 3-NP-treated mice, especially in the dorsal striatum
|
|
|
• striatal degeneration in 3-NP-treated mice
• however, calpain and PARP inhibitors suppress striatal neurodegeneration and behavioral impairments
|
behavior/neurological
|
|
• 3-NP treated mice exhibit increased motor impairment (neurological score based on: general slowness of displacement resulting from mild hindlimb impairment;, incoordination and marked gait abnormality; hindlimb paralysis; incapacity to move resulting from forelimb and hindlimb impairment) compared with wild-type mice
|
|
|
• 3-NP-treated mice travel less distance in an open-field test compared with wild-type mice that is more severe than in Ogg1tm1Skmi homozygotes
• 3-NP-treated mice are hypoactive in home cages compared with wild-type mice
• however, calpain and PARP inhibitors suppress striatal neurodegeneration and behavioral impairments
|
cellular
|
|
• striatal degeneration in 3-NP-treated mice
• however, calpain and PARP inhibitors suppress striatal neurodegeneration and behavioral impairments
|
|
|
• 3-NP treated mice exhibit an accumulation of 8-oxoG that results in the accumulation of single strand breaks in mitochondrial DNA of striatal medium spiny neurons and nuclear DNA of striatal microglia compared with wild-type mice
|
homeostasis/metabolism
immune system
|
|
• in 3-NP-treated mice, especially in the dorsal striatum
|
hematopoietic system
|
|
• in 3-NP-treated mice, especially in the dorsal striatum
|
Analysis Tools